GT Biopharma Presents Two Posters at the Society for

Poster #1: Tri-specific killer engagers target natural killer cells towards mesothelioma Poster #2: Enhancing NK cell function in the ‘cold’ tumor microenvironment of prostate cancer with a novel Tri-specific Killer…

GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s 37th Annual Meeting

BRISBANE – GT Biopharma, Inc. (the ‘Company’ or ‘GTB’) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell…

GT Biopharma Announces Two Poster Presentations at the

BRISBANE, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the…